ViroGates A/S AAQS
The The AAQS of ViroGates A/S (VIRO.CO) as of Nov 17, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
4
YoY
0.00%
Last updated:
ViroGates A/S has a current AAQS of 4.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock ViroGates A/S in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock ViroGates A/S in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The ViroGates A/S AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2018
4.00 DKK
Jan 1, 2019
4.00 DKK
Jan 1, 2020
4.00 DKK
Jan 1, 2021
4.00 DKK
Jan 1, 2022
4.00 DKK
Jan 1, 2023
4.00 DKK
Jan 1, 2024
4.00 DKK
Jan 1, 2025
4.00 DKK
| YEAR | AAQS | YoY |
|---|---|---|
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | 0.00% | |
| 4 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
ViroGates A/S Stock analysis
What does ViroGates A/S do? ViroGates A/S develops and markets prognostic products for the healthcare sector, focusing on the suPARnostic product line that measures soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The suPARnostic Quantitative Point of Care Quick Triage test is designed for patient triage in acute care settings, while the Quantitative ELISA Assay targets clinical routine use. Healthcare providers, including hospitals and clinics, purchase these products to assess immune activation levels and monitor disease progression, particularly for conditions like HIV-1-infection, malaria, tuberculosis, and sepsis. The company generates revenue through the sale of these diagnostic tools to healthcare institutions for use in patient care and disease management.
The suPARnostic product line serves as a marker for survival chances upon hospital admission and aids in early intervention by detecting elevated suPAR levels linked to increased inflammation and mortality risk. High suPAR levels are associated with infectious diseases such as Streptococcus pneumonia bacteraemia, pneumococcal pneumonia, and bacterial and viral CNS infections. Healthcare facilities utilize the quantitative tests to determine patient prognosis and guide treatment decisions, ensuring timely interventions that improve patient outcomes. ViroGates A/S monetizes its diagnostic solutions by supplying healthcare systems with tools that enhance clinical decision-making and patient monitoring capabilities.
ViroGates A/S targets healthcare providers who require rapid and accurate diagnostic tools for acute care and routine clinical use. The company's products are specifically tailored for monitoring immune activation in patients with infectious diseases, offering both point-of-care testing and laboratory-based assays. By providing these specialized diagnostic solutions, ViroGates A/S supports healthcare institutions in managing patient care more effectively, leading to better health outcomes and reduced mortality rates. Revenue is derived from the direct sale of suPARnostic tests to hospitals, clinics, and other clinical facilities that integrate these tools into their diagnostic workflows. ViroGates A/S is one of the most popular companies on Eulerpool.
Frequently Asked Questions about ViroGates A/S stock
The AAQS of ViroGates A/S is 4 in 2025.
On Eulerpool you can find the complete historical development of The AAQS ViroGates A/S since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — ViroGates A/S
All Key Metrics — ViroGates A/S
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth